i have got a reply from Jane:
"The company expects to update the market soon on its SubB2M programs. As INOVIQ has stated in its milestones, it is appointing a CRO for its SubB2M ovarian and breast cancer programs. This is an important milestone in the SubB2M program to advance assay development, optimisation and future validation of the tests."
so definitely we will see the some updates soon.
Ann: Update on Legal Proceedings and BARD1 Autoantibody Program, page-33
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
59.5¢ |
Change
0.035(6.25%) |
Mkt cap ! $65.61M | |||
| Open | High | Low | Value | Volume |
| 56.0¢ | 59.5¢ | 56.0¢ | $20.62K | 36.04K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 446 | 56.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 60.0¢ | 30002 | 3 |
View Market Depth
| Last trade - 15.57pm 23/08/2024 (20 minute delay) ? |
| IIQ (ASX) Chart |